Polaryx Therapeutics, Inc.
PLYX
$3.37
$0.092.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -23.70% | 12.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.47% | 10.18% | |||
| Operating Income | 6.47% | -10.18% | |||
| Income Before Tax | -4.55% | -41.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.55% | -41.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.55% | -41.87% | |||
| EBIT | 6.47% | -10.18% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -2.24% | -38.05% | |||
| Normalized Basic EPS | -2.05% | -38.30% | |||
| EPS Diluted | -2.24% | -38.05% | |||
| Normalized Diluted EPS | -2.05% | -38.30% | |||
| Average Basic Shares Outstanding | 2.36% | 2.51% | |||
| Average Diluted Shares Outstanding | 2.36% | 2.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||